Aventis/Genta Genasense meeting confirmed
Executive Summary
Date for review of Aventis/Genta's antisense drug Genasense by FDA's oncologic committee has been confirmed for May 3. Genta said it would receive an early May review by the committee (1"The Pink Sheet" Feb. 16, 2004, p. 6). The meeting will begin at 8 a.m. at the Hilton in Gaithersburg, Md...